At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALDX Aldeyra Therapeutics
Post-Mkt 03-25 16:04:03 EDT
1.85
-0.02
-1.07%
盘后1.84
-0.01-0.54%
16:02 EDT
High2.02Low1.76Vol4.51M
Open1.98D1 Closing1.87Amplitude13.90%
Mkt Cap111.30MTradable Cap89.69MTotal Shares60.16M
T/O8.32MT/O Rate9.30%Tradable Shares48.48M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Insider Makes Bold Move on Aldeyra Therapeutics Stock
TIPRANKS  ·  03-21
Insider Makes Bold Move on Aldeyra Therapeutics Stock
Aldeyra Therapeutics Principal Financial Officer Michael Alfieri acquires USD 7,100 of common shares
Reuters  ·  03-20
Aldeyra Therapeutics Principal Financial Officer Michael Alfieri acquires USD 7,100 of common shares
What's Going On With Aldeyra Therapeutics Stock On Thursday?
Benzinga_recent_news  ·  03-19
What's Going On With Aldeyra Therapeutics Stock On Thursday?
Levi & Korsinsky probes Aldeyra Therapeutics over potential securities fraud claims
Reuters  ·  03-19
Levi & Korsinsky probes Aldeyra Therapeutics over potential securities fraud claims
Aldeyra Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones  ·  03-18
Aldeyra Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.
HC Wainwright Downgrades Aldeyra Therapeutics to Neutral From Buy, Adjusts PT to $2 From $10
MT Newswires Live  ·  03-18
HC Wainwright Downgrades Aldeyra Therapeutics to Neutral From Buy, Adjusts PT to $2 From $10
Aldeyra downgraded to Neutral from Buy at H.C. Wainwright
TIPRANKS  ·  03-18
Aldeyra downgraded to Neutral from Buy at H.C. Wainwright
U.S. RESEARCH ROUNDUP-Factset, Lensar, Starbucks
Reuters  ·  03-18
U.S. RESEARCH ROUNDUP-Factset, Lensar, Starbucks
BUZZ-U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora
Reuters  ·  03-18
BUZZ-U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora
Aldeyra Therapeutics Shares Hit Record Low After US FDA Declines to Approve Eye Disorder Drug, Last Down 70%
THOMSON REUTERS  ·  03-17
Aldeyra Therapeutics Shares Hit Record Low After US FDA Declines to Approve Eye Disorder Drug, Last Down 70%
Aldeyra Therapeutics Shares Fall as Drug Rejected by Regulator on Efficacy Concerns
Dow Jones  ·  03-17
Aldeyra Therapeutics Shares Fall as Drug Rejected by Regulator on Efficacy Concerns
FDA issues Aldeyra CRL saying reproxalap NDA failed to demonstrate efficacy
TIPRANKS  ·  03-17
FDA issues Aldeyra CRL saying reproxalap NDA failed to demonstrate efficacy
How Did the FDA Shatter Investor Confidence In Aldeyra Therapeutics Stock (ALDX) Today?
TIPRANKS  ·  03-17
How Did the FDA Shatter Investor Confidence In Aldeyra Therapeutics Stock (ALDX) Today?
Aldeyra Therapeutics Shares Down 73% Premarket After US FDA Declines to Approve Eye Disorder Drug
THOMSON REUTERS  ·  03-17
Aldeyra Therapeutics Shares Down 73% Premarket After US FDA Declines to Approve Eye Disorder Drug
FDA issues complete response letter for Aldeyra’s reproxalap dry eye NDA
Reuters  ·  03-17
FDA issues complete response letter for Aldeyra’s reproxalap dry eye NDA
Aldeyra Therapeutics Inc - No Safety or Manufacturing Concerns Identified in Reproxalap Nda Review
THOMSON REUTERS  ·  03-17
Aldeyra Therapeutics Inc - No Safety or Manufacturing Concerns Identified in Reproxalap Nda Review
Aldeyra Therapeutics Inc - FDA States Reproxalap Nda Failed to Demonstrate Efficacy for Dry Eye Disease
THOMSON REUTERS  ·  03-17
Aldeyra Therapeutics Inc - FDA States Reproxalap Nda Failed to Demonstrate Efficacy for Dry Eye Disease
Aldeyra Therapeutics Receives Complete Response Letter From the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
THOMSON REUTERS  ·  03-17
Aldeyra Therapeutics Receives Complete Response Letter From the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
Aldeyra Therapeutics Inc - to Request Type a Meeting With FDA Within 30 Days per Pdufa Goals
THOMSON REUTERS  ·  03-17
Aldeyra Therapeutics Inc - to Request Type a Meeting With FDA Within 30 Days per Pdufa Goals
Aldeyra Therapeutics Inc - FDA Recommends Exploring Trial Failures; No Additional Trials Requested for Reproxalap
THOMSON REUTERS  ·  03-17
Aldeyra Therapeutics Inc - FDA Recommends Exploring Trial Failures; No Additional Trials Requested for Reproxalap

Introduction

Company Name.
Aldeyra Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Issue price:
--